ZNF143 activates gene expression in response to DNA damage and binds to cisplatin-modified DNA

International Journal of Cancer

Volumn 111, Issue 6, 2004, Pages 900-909

  Ishiguchi, Hiroshi ^a   Izumi, Hiroto ^a   Torigoe, Takayuki ^a   Yoshida, Yoichiro ^a   Kubota, Hiroshi ^b   Tsuji, Sadatoshi ^a   Kohno, Kimitoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b HSP Research Institute   (Japan)

Author keywords

Cisplatin; DNA damage; MRP S11; Staf; ZNF143

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; PROTEIN; STAF PROTEIN; TRANSCRIPTION FACTOR; TRANSPLATIN; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DNA DAMAGE; GAMMA IRRADIATION; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INDUCTION; HUMAN; HUMAN CELL; MRP S11 GENE; PRIORITY JOURNAL; PROMOTER REGION; ZNF143 GENE; ZNF76 GENE;

ANTINEOPLASTIC AGENTS; BASE SEQUENCE; CISPLATIN; DNA DAMAGE; DNA-BINDING PROTEINS; GENE EXPRESSION PROFILING; HUMANS; MITOCHONDRIAL PROTEINS; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS (GENETICS); RIBOSOMAL PROTEINS; RNA, MESSENGER; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; XENOPUS PROTEINS; ZINC FINGERS;

EID: 4143152992     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20358     Document Type: Article

References (34)

1. Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucl Acid Res Mol Biol 2001;67:93-130.
2. Brabec V. DNA modifications by antitumor platinum and ruthenium compounds: their recognition and repair. Prog Nucl Acid Res Mol Biol 2002;71:1-68.
3. Brabec V, Kasparkova J. Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updat 2002;5:147-61.
4. Fuertes MA, Alonso C, Ferez JM. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003;103:645-62.
5. Ise T, Nagatani G, Imamura T, Kato K, Takano H, Nomoto M, Izumi H, Ohmori H, Okamoto T, Ohga T, Uchiumi T, Kuwano M, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999;59:342-6.
6. Nagatani G, Nomoto M, Takano H, Ise T, Kato K, Imamura T, Izumi H, Makishima K, Kohno K. Transcriptional activation of the human HMG1 gene in cisplatin-resistant human cancer cells. Cancer Res 2001;61:1592-7.
7. Meighan-Mantha RL, Riegel AT, Suy S, Harris V, Wang FH, Lozano C, Whiteside TL, Kasid U. Ionizing radiation stimulates octamer factor DNA binding activity in human carcinoma cells. Mol Cell Biochem 1999;199:209-15.
8. Zhao H, Jin S, Fan F, Fan W, Tong T, Zhan Q. Activation of the transcription factor Oct-1 in response to DNA damage. Cancer Res 2000;60:6276-80.
9. Murakami T, Shibuya I, Ise T, Chen ZS, Akiyama S, Nakagawa M, Izumi H, Nakamura T, Maisuo K, Yamada Y, Kohno K. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 2001;93:869-74.
10. Torigoe T, Izumi H, Ise T, Murakami T, Uramoto H, Ishiguchi H, Yoshida Y, Tanabe M, Nomoto M, Kohno K. Vacuolar H(+)-ATPase: functional mechanisms and potential as a target for cancer chemotherapy. Anticancer Drugs 2002;13:237-43.
11. Torigoe T, Izumi H, Ishiguchi H, Uramoto H, Murakami T, Ise T, Yoshida Y, Tanabe M, Nomoto M, Itoh H, Kohno K. Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem 2002;277:36534-43.
12. Koc EC, Burkhart W, Blackburn K, Moseley A, Spremulli LL. The small subunit of the mammalian mitochondrial ribosome. J Biol Chem 2001;276:19363-74.
13. Schaub M, Myslinski E, Schuster C, Krol A, Carbon P. Staf, a promiscuous activator for enhanced transcription by RNA polymerases II and III. EMBO J 1997;16173-81.
14. Myslinski E, Krol A, Carbon P. ZNF76 and ZNF143 are two human homologs of the transcriptional activator Staf. J Biol Chem 1998;273:21998-2006.
15. Shen DW, Akiyama S, Schoenlein P, Pastan I, Gottesman MM. Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer 1995;71:676-83.
16. Nakagawa M, Nomura Y, Kohno K, Ono M, Mizoguchi H, Ogata J, Kuwano M. Reduction of drug accumulation in cisplatin-resistant variants of human prostatic cancer PC-3 cell line. J Urol 1993;150:1970-3.
17. Rincon JC, Engler SK, Hargrove BW, Kunkel GR. Molecular cloning of a cDNA encoding human SPH-binding factor, a conserved protein that binds to the enhancer-like region of the U6 small nuclear RNA gene promoter. Nucl Acids Res 1998;26:4846-52.
18. Uramoto H. Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, Yasumoto K, Funa K, Kohno K. p73 Interacts with c-Myc to regulate Y-box-binding protein-1 expression. J Biol Chem 2002;277:31694-702.
19. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-54.
20. Jung Y, Mikala Y, Lippard SJ. Kinetic studies of the TATA-binding protein interaction with cisplatin-modified DNA. J Biol Chem 2001; 276:43589-96.
21. Yoshida Y, Izumi H, Ise T, Uramoto H, Torigoe T, Ishiguchi H, Murakami T, Tanabe M, Nakayama Y, Itofi H, Kasai H, Kofino K. Human mitochondrial transcription factor A binds preferentially to oxidatively damaged DNA. Biochem Biophys Res Commun 2002; 295:945-51.
22. Evdokimova VM, Wei CL, Sitikov AS, Simonenko PN, Lazarev OA, Vasilenko KS, Ustinov VA, Hershey JW, Ovchinnikov LP. The major protein of messenger ribonucleoprotein particles in somatic cells is a member of the Y-box binding transcription factor family. J Biol Chem 1995;270:3186-92.
23. Davydova EK, Evdokimova VM, Ovchinnikov LP, Hershey JW. Overexpression in COS cells of p50, the major core protein associated with mRNA, results in translation inhibition. Nucl Acids Res 1997; 25:2911-6.
24. Hayakawa H, Uchiumi T, Fukuda T, Ashizuka M, Kohno K, Kuwano M, Sekiguchi M. Binding capacity of human YB-I protein for RNA containing 8-oxoguanine. Biochemistry 2002;41:12739-44.
25. Suzuki T, Terasaki M, Takemoto-Hori C, Hanada T, Ueda T, Wada A, Watanabe K. Proteomic analysis of the mammalian mitochondrial ribosome: identification of protein components in the 28 S small subunit. J Biol Chem 2001;276:33181-95.
26. Kartalou M, Essigmann JM. Recognition of cisplatin adducts by cellular proteins. Mutat Res 2001;478:1-21.
27. Zlatanova J, Yaneva J, Leuba SH. Proteins that specifically recognize cisplatin-damaged DNA: a clue to anticancer activity of cisplatin. FASEB J 1998;12:791-9.
28. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem Rev 1999;99:2467-98.
29. Cohen SM, Jamieson ER, Lippard SJ. Enhanced binding of the TATA-binding protein to TATA boxes containing flanking cisplatin 1,2-cross-links. Biochemistry 2000;39:8259-65.
30. Okamoto T, Izumi H, Imamura T, Takano H, Ise T, Uchiumi T, Kuwano M, Kohno K. Direct interaction of p53 with the Y-box binding protein, YB-1: a mechanism for regulation of human gene expression. Oncogene 2000;19:6194-202.
31. Imamura T, Izumi H, Nagatani G, Ise T, Nomoto M, Iwamoto Y, Kohno K. Interaction with p53 enhances binding of cisplatin-modified DNA by high mobility group 1 protein. J Biol Chem 2001;276:7534-40.
32. Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem 1997;272:23465-8.
33. Moggs JG, Szymkowski DE, Yamada M, Karran P, Wood RD. Differential human nucleotide excision repair of paired and mispaired cisplatin-DNA adducts. Nucl Acids Res 1997;25:480-91.
34. Wood RD, Mitchell M, Sgouros J, Lindahl T. Human DNA repair genes. Science 2001;291:1284-9.